EP1515748A4 - Anti-estrogen and immune modulator combinations for treating breast cancer - Google Patents

Anti-estrogen and immune modulator combinations for treating breast cancer

Info

Publication number
EP1515748A4
EP1515748A4 EP02793936A EP02793936A EP1515748A4 EP 1515748 A4 EP1515748 A4 EP 1515748A4 EP 02793936 A EP02793936 A EP 02793936A EP 02793936 A EP02793936 A EP 02793936A EP 1515748 A4 EP1515748 A4 EP 1515748A4
Authority
EP
European Patent Office
Prior art keywords
estrogen
breast cancer
immune modulator
treating breast
modulator combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02793936A
Other languages
German (de)
French (fr)
Other versions
EP1515748A2 (en
Inventor
David A Sirbasku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signe BioPharma Inc
Original Assignee
David A Sirbasku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David A Sirbasku filed Critical David A Sirbasku
Publication of EP1515748A2 publication Critical patent/EP1515748A2/en
Publication of EP1515748A4 publication Critical patent/EP1515748A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP02793936A 2001-11-14 2002-11-13 Anti-estrogen and immune modulator combinations for treating breast cancer Withdrawn EP1515748A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33280101P 2001-11-14 2001-11-14
US332801P 2001-11-14
PCT/US2002/036633 WO2003041654A2 (en) 2001-11-14 2002-11-13 Anti-estrogen and immune modulator combinations for treating breast cancer

Publications (2)

Publication Number Publication Date
EP1515748A2 EP1515748A2 (en) 2005-03-23
EP1515748A4 true EP1515748A4 (en) 2006-04-12

Family

ID=23299909

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02793936A Withdrawn EP1515748A4 (en) 2001-11-14 2002-11-13 Anti-estrogen and immune modulator combinations for treating breast cancer

Country Status (3)

Country Link
EP (1) EP1515748A4 (en)
AU (1) AU2002359401A1 (en)
WO (1) WO2003041654A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD20140054A2 (en) 2011-12-16 2014-10-31 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859585A (en) * 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
US4919937A (en) * 1984-01-20 1990-04-24 Mauvais Jarvis Pierre Percutaneous administration of tamoxifen
EP1366366A2 (en) * 2000-05-10 2003-12-03 David A. Sirbasku Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261787B1 (en) * 1996-06-03 2001-07-17 Case Western Reserve University Bifunctional molecules for delivery of therapeutics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919937A (en) * 1984-01-20 1990-04-24 Mauvais Jarvis Pierre Percutaneous administration of tamoxifen
US4859585A (en) * 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
EP1366366A2 (en) * 2000-05-10 2003-12-03 David A. Sirbasku Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRODIE A ET AL: "Aromatase inhibitors and their antitumor effects in model systems.", ENDOCRINE-RELATED CANCER. JUN 1999, vol. 6, no. 2, June 1999 (1999-06-01), pages 205 - 210, XP002367011, ISSN: 1351-0088 *
MCCORMICK DAVID L ET AL: "Exceptional chemopreventive activity of low-dose dehydroepiandrosterone in the rat mammary gland", CANCER RESEARCH, vol. 56, no. 8, 1996, pages 1724 - 1726, XP008057031, ISSN: 0008-5472 *
ROSSO R ET AL: "ADJUVANT SYSTEMIC TREATMENT OF RESECTABLE BREAST CANCER ELEVEN YEARS RESULTS OF A MONOINSTITUTIONAL CHEMO-HORMONE-IMMUNOTHERAPY TRIAL", ANTICANCER RESEARCH, vol. 9, no. 4, 1989, pages 1153 - 1156, XP008057015, ISSN: 0250-7005 *
SAVAGE P ET AL: "A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily", BRITISH JOURNAL OF CANCER, vol. 74, no. 9, 1996, pages 1482 - 1486, XP002073161, ISSN: 0007-0920 *
SAWAI K ET AL: "CHEMO-ENDOCRINE-IMMUNOTHERAPY WITH ADRIAMYCIN TAMOXIFEN AND OK-432 PICIBANIL FOR ADVANCED BREAST CANCER", JOURNAL OF JAPAN SOCIETY FOR CANCER THERAPY, vol. 19, no. 6, 1984, pages 1315 - 1320, XP008057016, ISSN: 0021-4671 *

Also Published As

Publication number Publication date
EP1515748A2 (en) 2005-03-23
WO2003041654A2 (en) 2003-05-22
WO2003041654A3 (en) 2005-01-06
AU2002359401A1 (en) 2003-05-26

Similar Documents

Publication Publication Date Title
IL251270A0 (en) Cancer treatment
EP1399460A4 (en) Breast cancer-associated genes and uses thereof
SI1176964T1 (en) Uses of et743 for treating cancer
EP1320376A4 (en) Treatment of prostate cancer
MXPA03008582A (en) Agents and methods for treatment of cancer.
EP1694364A4 (en) System for treating and preventing breast cancer
EP1416960A4 (en) Vegfr-1 antibodies to treat breast cancer
AU2002351374A8 (en) Antibodies to treat cancer
GB0005257D0 (en) Breast cancer hormonal therapy
EP1401377A4 (en) Methods for treating cancer
IL161762A0 (en) Estradiol inhibiting agents in breast cancer
EP1401494A4 (en) Tumor therapy
EP1515748A4 (en) Anti-estrogen and immune modulator combinations for treating breast cancer
GB0026015D0 (en) Cancer treatment
IL149281A0 (en) Treatment of cancer
AU2002366364A8 (en) E2f and cancer therapy
EP1463511A4 (en) Combination cancer therapy
GB0223325D0 (en) Treating cancer
AU2002360454A8 (en) Methods and compositions for treating cancer
GB0027780D0 (en) Treating cancer
GB0007254D0 (en) Treating cancer
GB9911302D0 (en) Treating cancer
GB9908176D0 (en) Cancer treatment
GB0105244D0 (en) Cancer treatment methods and compositions
GB2383538B (en) Cancer treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SIRBASKU, DAVID A.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SIRBASKU, DAVID A.

17P Request for examination filed

Effective date: 20050615

A4 Supplementary search report drawn up and despatched

Effective date: 20060224

17Q First examination report despatched

Effective date: 20070214

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SIGNE BIOPHARMA INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SIRBASKU, DAVID A.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SIGNE BIOPHARMA INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080710